Wonderful installment of #LipidsMadeSimple by @nationallipid Drs @CBallantyneMD @MarlysLPA lipid.org/wp-content/upl… Lipoprotein(a) @NYUCVDPrevent
Dr. James Underberg
Verified account This account is verified. Learn more@lipiddoc
Lipidologist🩺🧬 @nyulangone @NYUCVDPrevent PastPresident @NationalLipid & @LipidBoard President @NLAFoundation Dir. @BHLipidClinic T/RT≠endorsements/med advice
8.5K Following 14K Followers 22K Posts
Latest posts 5
The Lp(a) story gets more interesting every day ! Wonderful paper @Lpa_Doc
We've long focused on Lp(a) molar concentration, but Lp(a) biology is more complex. In our new paper led by Kaloyan Takov and Manual Mayr @Vascular_Prot, shows that native Lp(a) carries an APOE-associated triglyceride signature. TG(52:3) and TG(52:4), enriched in polyunsaturated fatty acids, are linked to incident MACE and may represent oxidizable lipid cargo contributing to cardiovascular risk. Lots of new stuff on the way identifying specific components of Lp(a) (chol, TG, OxPL) and CVD risk @DavidErlinge @GreggWStone @society_eas atherosclerosis-journal.com/article/S0021-…View quoted post on X
Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) - Journal of Clinical Lipidology lipidjournal.com/article/S1933-… via @LipidJournal @NYUCVDPrevent @FamilyHeartFdn @foundationofnla #HoFH #FindFH
www.lipidjournal.com Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety... Lomitapide is an oral microsomal triglyceride transfer protein inhibitor approved for homozygous familial hypercholesterolemia (HoFH). Looking forward to chatting with my long time friend , colleague and all around great guy Dr Fred Feit this Wed Morning a 6AM on @SIRIUSXM @NYUDocs @nyulangone discussing #lipids #Lipoproteins #triglycerides @nationallipid @foundationofnla Please tune in and call in with your questions !!
Very excited to see so much interest in the field of CV Prevention and Lipidology Welcome Josh ! @NYUCVDPrevent @nationallipid @lipidboard
We’re thrilled to welcome Dr. Joshua Hyman as our newest Preventive Cardiology Fellow-the 17th fellow in our program’s history!
Dr. Hyman earned his medical degree at Yale and recently completed the Yale Internal Medicine-Pediatrics Residency Program.
med.nyu.edu/departments-in…View quoted post on X
